IPSC — Century Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $44.69m
- -$120.43m
- $6.59m
- 20
- 76
- 54
- 49
Annual income statement for Century Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 5.2 | 2.23 | 6.59 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 53.9 | 94.9 | 139 | 149 | 145 |
| Operating Profit | -53.9 | -94.9 | -134 | -147 | -138 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -53.6 | -95.8 | -131 | -135 | -125 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -53.6 | -95.8 | -131 | -137 | -127 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -53.6 | -95.8 | -131 | -137 | -127 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -53.6 | -95.8 | -131 | -137 | -127 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.53 | -2.96 | -2.09 | -2.04 | -1.57 |